CSL Behring Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • CSL Behring's estimated annual revenue is currently $1.4B per year.(i)
  • CSL Behring's estimated revenue per employee is $155,000

Employee Data

  • CSL Behring has 9234 Employees.(i)
  • CSL Behring grew their employee count by 5% last year.

CSL Behring's People

NameTitleEmail/Phone
1
Co-Founder & COOReveal Email/Phone
2
Sr VP Global EngineeringReveal Email/Phone
3
EVP, Head Research & DevelopmentReveal Email/Phone
4
Head Pharmacology & ToxicologyReveal Email/Phone
5
Head Execution Systems EUReveal Email/Phone
6
VP Researh and Development and Therapeutic AreaReveal Email/Phone
7
Head IT Demand & Portfolio ManagementReveal Email/Phone
8
Head CQA Operations AmericasReveal Email/Phone
9
Head FinanceReveal Email/Phone
10
Head Global Marketing, Cardiovascular and Metabolic TAReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.6M100%N/AN/A
#2
$4M2613%N/AN/A
#3
$0.9M6-14%N/AN/A
#4
$1.1M70%N/AN/A
#5
$10.9M703%N/AN/A
#6
$0.7M929%N/AN/A
#7
$4M26-16%N/AN/A
#8
$1.7M1122%N/AN/A
#9
$7.6M492%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is CSL Behring?

ZLB develops, produces and markets high-quality biological drugs made from human plasma and operates plasma collection centres and a laboratory in the United States of America.ZLB is one of the world’s leading manufacturers of intravenously administered polyvalent immunoglobulins. Immunoglobulin preparations and albumin solutions are manufactured in accordance with international safety and quality standards at the production plants of ZLB Bioplasma AG in Bern (Switzerland) which have been licensed by the Swiss health authorities and the US FDA.

keywords:N/A

N/A

Total Funding

9234

Number of Employees

$1.4B

Revenue (est)

5%

Employee Growth %

N/A

Valuation

N/A

Accelerator

CSL Behring News

2022-03-30 - Companies want your plasma, and they're willing to pay big ...

At CSL Plasma, however, there is no exchange of money due to the fact that the plasma collected is then used by CSL Behring for their litany of...

2022-03-30 - EtranaDez, Potential Hemophilia B Gene Therapy, Under ...

... by CSL Behring to approve the potential gene therapy EtranaDez ... CSL Behring's head of global regulatory affairs, said in a press...

2022-03-22 - European Medicines Agency Commences Review of Novel ...

"As the first gene therapy candidate for hemophilia B, this pivotal regulatory milestone brings CSL Behring one step closer to delivering on the...

2021-10-04 - Ther­mo Fish­er ex­pands in­to Switzer­land as part of CSL col­lab­o­ra­tion

Just days af­ter Ther­mo Fish­er Sci­en­tif­ic prepped to ex­pand a St. Louis plant, the com­pa­ny an­nounced it’s tak­ing over a new, 1.5 mil­lion-square-foot site in Switzer­land with plans to add 200 new em­ploy­ees. The move is a part of a May 2020 part­ner­ship with CSL and the site, slat­ ...

2021-03-31 - Uplifting Athletes Presents $140,000 in Rare Disease Research Grants at 2021 Young Investigator Draft

Uplifting Athletes Young Investigator Draft Presented by CSL Behring PHILADELPHIA (PRWEB) March 31, 2021 Uplifting Athletes, a nonprofit organization serving the Rare Disease Community, awarded $140,000 in medical research grants last night at its Young Investigator Draft Presented by CSL Behr ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2339.1M92828%N/A
#2
$12450M104554%$25M